CELC Quote, Financials, Valuation and Earnings

Azitra, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of 23.36%. Celcuity, Inc.'s return on equity of -158.5% beat Azitra, Inc.'s return on equity of -245.12%.

Celcuity, Inc. has a consensus price target of $106.44, signalling upside risk potential of 0.77%. On the other hand Azitra, Inc. has an analysts' consensus of $2.70 which suggests that it could grow by 644.62%. Given that Azitra, Inc. has higher upside potential than Celcuity, Inc., analysts believe Azitra, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Azitra, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azitra, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Azitra, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Azitra, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is lower than Azitra, Inc.'s net income of -$2.8M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Azitra, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 6.94x for Azitra, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Olema Pharmaceuticals, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.

Celcuity, Inc. has a consensus price target of $106.44, signalling upside risk potential of 0.77%. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $36.50 which suggests that it could grow by 34.14%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Celcuity, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Olema Pharmaceuticals, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is lower than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rapt Therapeutics, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Rapt Therapeutics, Inc.'s return on equity of -67.79%.

Celcuity, Inc. has a consensus price target of $106.44, signalling upside risk potential of 0.77%. On the other hand Rapt Therapeutics, Inc. has an analysts' consensus of $65.00 which suggests that it could grow by 88.6%. Given that Rapt Therapeutics, Inc. has higher upside potential than Celcuity, Inc., analysts believe Rapt Therapeutics, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Rapt Therapeutics, Inc. has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.168%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapt Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Rapt Therapeutics, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Rapt Therapeutics, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is lower than Rapt Therapeutics, Inc.'s net income of -$17.6M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Rapt Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 54.16x for Rapt Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Replimune Group, Inc.'s return on equity of -82.53%.

Celcuity, Inc. has a consensus price target of $106.44, signalling upside risk potential of 0.77%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 18.49%. Given that Replimune Group, Inc. has higher upside potential than Celcuity, Inc., analysts believe Replimune Group, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.209, which suggesting that the stock is 79.061% less volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.125%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.